Breast biomarker immunocytochemistry

Soheila Korourian; Asangi R. Kumarapeli; Vicki Klimberg

doi:10.1016/B978-0-323-35955-9.00014-3

Breast biomarker immunocytochemistry

Soheila Korourian, Asangi R. Kumarapeli, Vicki Klimberg

Surgery

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Organization, more than 20 morphologic subtypes of breast cancer have been recognized. By gene expression, invasive breast cancer is classified into at least four major subtypes; luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)/neu-positive, and triple-negative cancers. The biology and the prognosis of these subtypes are vastly different. It is well recognized that genetic profiles of these cancer subtypes are also interlinked with the traditional breast biomarkers. According to the US National Institutes of Health's Working Group and Biomarkers Consortium, a biomarker is a characteristic that is objectively measured as an indicator of normal biological processes, pathogenic processes, or a pharmacologic response to a therapeutic intervention.

Original language	English (US)
Title of host publication	The Breast
Subtitle of host publication	Comprehensive Management of Benign and Malignant Diseases
Publisher	Elsevier Inc.
Pages	197-206.e6
ISBN (Print)	9780323359559
DOIs	https://doi.org/10.1016/B978-0-323-35955-9.00014-3
State	Published - Aug 24 2017

Keywords

Biomarker
Hormone receptors
Immunohistochemistry
Pathology

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/B978-0-323-35955-9.00014-3

Cite this

@inbook{6e6792d3c2a94c71988ae53be8c9ee6f,

title = "Breast biomarker immunocytochemistry",

abstract = "Organization, more than 20 morphologic subtypes of breast cancer have been recognized. By gene expression, invasive breast cancer is classified into at least four major subtypes; luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)/neu-positive, and triple-negative cancers. The biology and the prognosis of these subtypes are vastly different. It is well recognized that genetic profiles of these cancer subtypes are also interlinked with the traditional breast biomarkers. According to the US National Institutes of Health's Working Group and Biomarkers Consortium, a biomarker is a characteristic that is objectively measured as an indicator of normal biological processes, pathogenic processes, or a pharmacologic response to a therapeutic intervention.",

keywords = "Biomarker, Hormone receptors, Immunohistochemistry, Pathology",

author = "Soheila Korourian and Kumarapeli, {Asangi R.} and Vicki Klimberg",

year = "2017",

month = aug,

day = "24",

doi = "10.1016/B978-0-323-35955-9.00014-3",

language = "English (US)",

isbn = "9780323359559",

pages = "197--206.e6",

booktitle = "The Breast",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Breast biomarker immunocytochemistry

AU - Korourian, Soheila

AU - Kumarapeli, Asangi R.

AU - Klimberg, Vicki

PY - 2017/8/24

Y1 - 2017/8/24

N2 - Organization, more than 20 morphologic subtypes of breast cancer have been recognized. By gene expression, invasive breast cancer is classified into at least four major subtypes; luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)/neu-positive, and triple-negative cancers. The biology and the prognosis of these subtypes are vastly different. It is well recognized that genetic profiles of these cancer subtypes are also interlinked with the traditional breast biomarkers. According to the US National Institutes of Health's Working Group and Biomarkers Consortium, a biomarker is a characteristic that is objectively measured as an indicator of normal biological processes, pathogenic processes, or a pharmacologic response to a therapeutic intervention.

AB - Organization, more than 20 morphologic subtypes of breast cancer have been recognized. By gene expression, invasive breast cancer is classified into at least four major subtypes; luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)/neu-positive, and triple-negative cancers. The biology and the prognosis of these subtypes are vastly different. It is well recognized that genetic profiles of these cancer subtypes are also interlinked with the traditional breast biomarkers. According to the US National Institutes of Health's Working Group and Biomarkers Consortium, a biomarker is a characteristic that is objectively measured as an indicator of normal biological processes, pathogenic processes, or a pharmacologic response to a therapeutic intervention.

KW - Biomarker

KW - Hormone receptors

KW - Immunohistochemistry

KW - Pathology

UR - http://www.scopus.com/inward/record.url?scp=85054329014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054329014&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-35955-9.00014-3

DO - 10.1016/B978-0-323-35955-9.00014-3

M3 - Chapter

AN - SCOPUS:85054329014

SN - 9780323359559

SP - 197-206.e6

BT - The Breast

PB - Elsevier Inc.

ER -

Breast biomarker immunocytochemistry

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this